COVID-19 | Diagnostics | Therapeutics | WHO
WHO recommended follow-up care, low-dose anticoagulants for COVID-19 patients
On Jan. 26, 2021, WHO recommends that patients who have COVID-19 – both confirmed and suspected – should…
-
-
Antibody infusions prevented acquisition of some HIV strains, NIH studies found
On Jan. 26, 2021, NIH researchers announced that an investigational anti-HIV antibody delivered intravenously once every eight weeks…
-
Abbott’s panbio rapid antigen test received CE Mark for asymptomatic screening and sample collection
On Jan. 26, 2021, Abbott announced it had received CE Mark for two new uses of its Panbioﾙ…
-
Vaxart announced additional preclinical COVID-19 oral vaccine data and publication
On Jan. 26, 2021, Vaxart announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a…
-
Sorrento announced positive preliminary results of phase 1b study of COVI-MSC for treatment of ICU COVID-19 patients
On Jan. 26, 2021, Sorrento Therapeutics announced positive preliminary results from its Phase 1b study of human allogeneic…
-
Moderna provided U.S. COVID-19 vaccine supply update
On Jan. 26, 2021, Moderna reported that 30.4 million doses have been supplied to the U.S. Government to…
-
Data showed Lilly’s neutralizing antibodies bamlanivimab and etesevimab reduced risk of COVID-19 hospitalizations and death by 70 percent
On Jan. 26, 2021, Eli Lilly announced that bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together…
-
OraSure’s OMNIgene-ORAL saliva collection kit selected by Chronomics for use in UK Government travel COVID-19 testing
On Jan. 26, 2021, OraSure Technologies announced that Chronomics had selected the OMNIgene-ORAL (OME-505) saliva collection device as…
-
BioReference Laboratories teamed-up with the NBA and NHL to provide players and staff with COVID-19 testing
On Jan. 26, 2021, BioReference Laboratories, an OPKO Health company, announced COVID-19 testing agreements for players and officials,…
-
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
-
Low-dose aspirin may improve pregnancy chances for women with one or two prior miscarriages
On Jan. 25, 2021, the National Institutes of Health (NIH) announced that in large clinical trial conducted worldwide,…
-
Merck discontinued development of SARS-CoV-2/COVID-19 vaccine candidates
On Jan. 25, 2021, Merck announced that the company had discontinued development of its SARS-CoV-2/COVID-19 vaccine candidates, V590…
-
Nirmidas Biotech received FDA Emergency Use Authorization for its COVID-19 rapid antibody fingerstick test
On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid…
-
Moderna COVID-19 vaccine retained neutralizing activity against emerging variants identified in UK and South Africa
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
-
OHSU study revealed SARS-CoV-2 reacted to antibodies of virus from 2003 SARS outbreak
On Jan. 25, 2021, Oregon Health & Science University (OHSU) announced a new study demonstrated that antibodies generated…
-
Clinical data showed BD antigen test may be more selective in detecting infectious COVID-19 than molecular tests
On Jan. 25, 2021, BD (Becton, Dickinson) announced the publication of a peer-reviewed study that showed BD’s antigen…
-
Mateon launched mobile app, ARTIHealthTM, remote for respiratory health assessment
On Jan. 25, 2021, Mateon Therapeutics announced that it was launching its mobile app, ARTIHealthTM, for respiratory health…
-
PRINCIPLE found antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19
On Jan. 25, 2021, scientists at the University of Oxford reported that after reviewing interim analyses of both…
-
Humanigen and Emergent BioSolutions announced CDMA for phase 3 COVID-19 therapeutic candidate Lenzilumabﾙ
On Jan. 25, 2021, Emergent BioSolutions and Humanigen announced a contract development and manufacturing (CDMO) services agreement to…
-
SARS-CoV-2 needs cholesterol to invade cells and form mega cells
On Jan. 25, 2021, HHMI investigators reported that cholesterol, the waxy compound better known for clogging arteries, helps…
-
Medigen’s COVID-19 vaccine announced first participant dosed in phase 2 clinical trial in Taiwan
On Jan. 25, 2021, Medigen Vaccine Biologics and Dynavax Technologies announced that the first participant had been dosed…
-
Full-dose blood thinners decreased need for life support and improved outcome in COVID-19 patients
On Jan. 22, 2021, the NIH announced that in large clinical trial conducted worldwide, full dose anti-coagulation (blood…
-
Novavax and Government of Canada finalize advance purchase agreement for COVID-19 vaccine
On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to…
-
Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19
On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…
-
Biotechnology | Cardiology | Disease | FDA | Therapeutics
FDA approved Aurinia Pharmaceuticals LUPKYNIS (voclosporin) for adults with active lupus nephritis
On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved LUPKYNISTM…
-
Pfizer and BioNTech reached agreement with COVAX for advance purchase of vaccine to combat COVID-19
On Jan. 22, 2021, Pfizer and BioNTech announced an advance purchase agreement with COVAX for up to 40…
-
COVAX announced new agreement, plans for first deliveries
On Jan. 22, 2021, COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for…
-
Moderna announced first participant dosed in phase 1/2 study of COVID-19 vaccine in Japan led by Takeda
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
-
Patients in cancer remission at high risk for severe COVID-19 illness
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
-
Janssen announced FDA approval of CABENUVA, the first long-acting HIV treatment regimen
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenﾒs rilpivirine and ViiV…
